5-Amino-1MQ: Clinical Guide for Prescribing Practices
5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme overexpressed in adipose tissue that is associated with obesity and metabolic dysfunction. By blocking NNMT, 5-Amino-1MQ promotes fat cell energy expenditure and reduces lipid accumulation. It is increasingly used as an adjunct to GLP-1 weight loss protocols for enhanced body composition outcomes.
Also Known As
How 5-Amino-1MQ Works
5-Amino-1MQ selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide using SAM (S-adenosyl methionine) as a methyl donor [1]. NNMT is overexpressed in white adipose tissue of obese individuals, where it reduces intracellular NAD+ and SAM concentrations, impairing cellular energy metabolism [2]. By blocking NNMT, 5-Amino-1MQ restores NAD+ and SAM levels in adipocytes, increasing energy expenditure and promoting a metabolically active phenotype in fat cells [1].
Clinical Evidence
Preclinical research by Neelakantan et al. (2018) demonstrated that selective NNMT inhibition in diet-induced obese mice reduced body weight and white adipose tissue mass without affecting food intake [1]. Kraus et al. (2014) established that NNMT is overexpressed in adipose tissue of obese individuals and that its knockdown increases energy expenditure in adipocytes [2]. In vitro studies confirm that NNMT inhibition increases NAD+ content, activates SIRT1 signaling, and reduces lipid accumulation [3]. Human clinical trial data remains limited, with the evidence base primarily consisting of cell culture and animal models.
Clinical Uses
Patient Selection and Screening
Best suited as an adjunct therapy for patients already on GLP-1 or incretin-based weight loss programs who seek enhanced body composition outcomes (fat loss with lean mass preservation) [1]. Also appropriate for patients with metabolic syndrome markers who prefer oral administration. Not recommended as monotherapy for clinically significant obesity [3]. Patients should be counseled that human clinical trial data is limited and prescribing is based on mechanistic rationale and clinical experience.
Dosing and Administration
Oral dosing typically ranges from 50mg to 150mg daily, with most protocols using 100mg daily as standard [1]. Some clinicians dose at 50mg twice daily for sustained levels. Injectable formulations (subcutaneous) are used at lower doses. Treatment duration is commonly 8-12 weeks, often cycled. Can be administered with or without food. Monitor metabolic markers (lipid panel, fasting glucose) to assess response [2]. Dosing should be individualized based on clinical judgment and patient goals.
Route: Oral capsule, subcutaneous injection
Protocol notes: Administered as oral capsule (50-150mg daily) or subcutaneous injection. Often used in combination with GLP-1 agonists, dietary intervention, and exercise programs. Duration of use varies by clinical indication and patient response.
Side Effects and Monitoring
Clinical Considerations
Practice Economics
5-Amino-1MQ is typically priced at $100-250 per month retail, with wholesale costs from compounding pharmacies in the $30-60 range per course. It functions as a high-margin add-on to existing GLP-1 weight loss programs, increasing per-patient revenue without requiring additional office visits [3]. Practices positioning full metabolic optimization (beyond appetite suppression alone) can use 5-Amino-1MQ to differentiate their programs.
FDA Category Status
Compounding eligibility varies; verify current FDA status before prescribing
FDA bulk drug substance category determines compounding eligibility. Category designations are subject to change; always verify the current status before prescribing. This information is provided for clinical reference and does not constitute legal or regulatory advice.
Pharmacy Integrations
Prescribe 5-Amino-1MQ through Karpa's integrated compounding pharmacy network with one-click ordering and direct-to-patient fulfillment.
Frequently Asked Questions
How does 5-Amino-1MQ work differently from GLP-1 medications?
Can 5-Amino-1MQ be combined with semaglutide or tirzepatide?
What is the current evidence base for 5-Amino-1MQ?
References
- Neelakantan et al. - Selective and Membrane-Permeable NNMT Inhibitors for Obesity (Biochemical Pharmacology 2018)
- Kraus et al. - NNMT Overexpression in Adipose Tissue and Its Role in Obesity (Nature 2014)
- Pissios - NNMT: A Promising Drug Target for Obesity (Trends in Endocrinology and Metabolism 2017)
Related Peptides in Weight Loss & Metabolic
Disclaimer: This information is intended for licensed healthcare providers only and does not constitute medical, legal, or regulatory advice. Clinical decisions should be based on your professional judgment, current evidence, and applicable state and federal regulations. Always verify FDA category status and compounding eligibility before prescribing. Content is reviewed periodically but may not reflect the most recent regulatory changes.
Prescribe 5-Amino-1MQ Through Karpa
Streamline your peptide prescribing workflow with integrated pharmacy ordering, patient tracking, and compliance documentation.
Prescribe 5-Amino-1MQ Through Karpa